The Clorox Company (NYSE:CLX) Shares Bought by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH raised its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 584.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,895 shares of the company's stock after buying an additional 7,596 shares during the period. Siemens Fonds Invest GmbH's holdings in Clorox were worth $1,445,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Clorox in the 4th quarter worth $259,041,000. FMR LLC increased its stake in shares of Clorox by 75.4% in the 4th quarter. FMR LLC now owns 1,361,758 shares of the company's stock worth $221,163,000 after purchasing an additional 585,526 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Clorox by 549.8% in the 4th quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock worth $88,144,000 after purchasing an additional 459,203 shares in the last quarter. ExodusPoint Capital Management LP increased its stake in shares of Clorox by 187.9% in the 4th quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock worth $113,508,000 after purchasing an additional 456,114 shares in the last quarter. Finally, Man Group plc increased its stake in shares of Clorox by 154.6% in the 4th quarter. Man Group plc now owns 570,503 shares of the company's stock worth $92,655,000 after purchasing an additional 346,449 shares in the last quarter. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Pierre R. Breber bought 4,000 shares of the company's stock in a transaction on Wednesday, May 7th. The stock was bought at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at approximately $546,280. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.57% of the stock is owned by company insiders.

Clorox Price Performance

NYSE CLX traded down $1.66 during trading hours on Monday, hitting $130.23. 1,406,696 shares of the company's stock traded hands, compared to its average volume of 1,342,194. The Clorox Company has a 52-week low of $129.19 and a 52-week high of $171.37. The company has a market capitalization of $16.05 billion, a PE ratio of 35.58, a PEG ratio of 2.62 and a beta of 0.60. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The firm's 50-day moving average is $138.04 and its 200-day moving average is $150.78.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). The firm had revenue of $1.67 billion during the quarter, compared to analysts' expectations of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The business's quarterly revenue was down 8.0% on a year-over-year basis. During the same period last year, the company earned $1.71 EPS. Equities analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Analyst Ratings Changes

CLX has been the subject of several recent analyst reports. Citigroup dropped their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a report on Monday, April 14th. Morgan Stanley dropped their target price on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. UBS Group dropped their target price on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Finally, Wells Fargo & Company dropped their target price on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $151.23.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.